USP30-AS1 is notably up-regulated in breast cancer tissues. (IMAGE)
Caption
(A) The expression of USP30-AS1 in normal tissues (n = 113) and breast cancer tissue (n = 1104), and the data were obtained from the TCGA breast cancer datasets.
(B) The expression of USP30-AS1 in various subtypes of breast cancer, including triple-negative breast Cancer (n = 116), HER2+ enriched breast Cancer (n = 37), luminal A (n = 375) and luminal B breast Cancer (n = 166).
(C) The expression of USP30-AS1 in breast cancer tissues and normal tissues. Data were obtained from GSE61304, Mann–Whitney U test.
(D) USP30-AS1 expression levels were determined by qRT-PCR in MCF10A, MCF-7, and MDA-MB-231 cell lines.
(E) The expression of USP30-AS1 in normal breast tissues (n = 84) and breast cancer tissues (n = 176) was determined by in situ hybridization.
(F) CHIP Base, Gene Cards, and Animal TFDB websites were utilized to predict the transcription factors of USP30-AS1.
(G) Correlation analysis of SPI1 and USP30-AS1 in breast cancer tissues (n = 1089).
(H) The expression levels of SPI1 in normal (n = 113) and breast cancer tissues (n = 1104), and the data were obtained from TCGA breast cancer datasets.
(I) The binding site of SPI1 in the promoter region of USP30-AS1 was obtained from JASPAR website.
(J) qRT-PCR showed that knockdown of SPI1 down-regulates the expression of USP30-AS1.
(K) Dual luciferase reporter assay was conducted to assess the effect of SPI1 siRNA on transcriptional activity of the USP30-AS1.
(L) The interaction between SPI and USP30-AS1 promoter was determined by ChIP assay. TGGA, the cancer genome atlas.
Credit
Yapei Jiang, Weijie Liao, Qilei Xin, Ruonan Wang, Guanglan Lin, Jia Li, Zijian Yang, Shiyue Yang, Haowei Zhang, Xiaolin Li, Qian Peng, Yaou Zhang, Weidong Xie, Naihan Xu
Usage Restrictions
Credit must be given to the creator. Only noncommercial uses of the work are permitted. No derivatives or adaptations of the work are permitted.
License
CC BY-NC-ND